Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Glucose–insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity

International Journal of Obesity volume 32, pages 436–442 (2008)Cite this article

Abstract

Objective:

Obese patients with schizophrenia being treated with clozapine and non-psychiatric obese are often assumed to share the same physiological changes in obesity. The aim of this study was to identify possible metabolic and hormonal differences between non-psychiatric obese subjects (OB) and obese patients with schizophrenia being treated with clozapine (OSC).

Subjects:

Fifty-one normal healthy subjects (Nor, body mass index (BMI):23.2±0.3), 50 OB (BMI:31.7±0.7) and 71 OSC (BMI:30.4±0.5).

Measurements:

Anthropometric, metabolic and hormonal parameters were determined by anthropometry, enzyme autoanalyzer, immunoassay and enzyme-linked immunosorbent assay.

Results:

Triglyceride, total cholesterol divided by high-density lipoprotein (HDL) cholesterol (TC/HDL) and leptin levels were significantly higher whereas the HDL and the molar ratio of insulin-like growth factor-1 (IGF-1), and insulin-like growth factor binding protein (IGFBP)-3 levels were significantly lower in both OB and OSC groups than those in the Nor group. Compared to normal subjects, insulin and homeostasis model assessment (HOMA) index levels were significantly higher in OSC, and, in OSC, insulin sensitivity and insulin-like growth factor (IGF)-1 were significantly lower. Although the anthropometric parameters in the OB and OSC groups were similar, in the OSC group the waist-to-hip ratio (WHR), insulin levels and HOMA index were significantly higher, while insulin sensitivity, cholesterol, low-density lipoprotein (LDL) cholesterol, TC/HDL, LDL/HDL, IGF-1 and IGF-1/IGFBP-3 molar ratio were lower, than those of the OB group.

Conclusion:

Insulin homeostasis and lipid profiles in clozapine-treated schizophrenic obesity were different from those in non-psychiatric obesity with similar anthropometric parameters, body weight and BMI. Among the three groups, the highest fasting insulin, the lowest insulin sensitivity and the highest HOMA index occurred in the OSC group. The OSC group was characterized by impaired glucose–insulin homeostasis, abnormal lipid profiles and hormonal changes in the GH-IGF-IGFBP axis and in leptin.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Newcomer JW . Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl 1): 1–93.

    CAS  PubMed  Google Scholar 

  2. Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter Jr WT . Adverse effects and laboratory parameters of high-dose olanzapine vs clozapine in treatment-resistant schizophrenia. Ann Clin Psychiatry 2003; 15: 181–186.

    Article  PubMed  Google Scholar 

  3. Bitter I, Dossenbach MR, Brook S, Feldman PD, Metcalfe S, Gagiano CA et al. Olanzapine HGCK Study Group. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 173–180.

    Article  CAS  PubMed  Google Scholar 

  4. Newcomer JW . Metabolic risk during antipsychotic treatment. Clin Ther 2004; 26: 1936–1946.

    Article  CAS  PubMed  Google Scholar 

  5. Ananth J, Parameswaran S, Gunatilake S . Side effects of atypical antipsychotic drugs. Curr Pharm Des 2004; 10: 2219–2229.

    Article  CAS  PubMed  Google Scholar 

  6. Bunce II DF, Jones LR, Badger LW, Jones SE . Medical illness in psychiatric patients: barriers to diagnosis and treatment. South Med J 1982; 75: 941–944.

    Article  Google Scholar 

  7. Goldman LS . Medical illness in patients with schizophrenia. J Clin Psychiatry 1999; 60 (Suppl 21): 10–15.

    PubMed  Google Scholar 

  8. Nasrallah HA . Factors in antipsychotic drug selection: tolerability considerations. CNS Spectr 2003; 8 (11 Suppl 2): 23–25.

    Article  PubMed  Google Scholar 

  9. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC . The effects of novel antipsychotics on glucose and lipid levels. J Clin psychiatry 2002; 63: 856–865.

    Article  CAS  PubMed  Google Scholar 

  10. Melkersson KI, Dahl ML . Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 2003; 170: 157–166.

    Article  CAS  Google Scholar 

  11. Baymiller SP, Ball P, McMahon RP, Buchanan RW . Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res 2003; 59: 49–57.

    Article  PubMed  Google Scholar 

  12. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R . Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J psychiatry 2002; 159: 561–566.

    Article  PubMed  Google Scholar 

  13. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agent. Arch Gen Psychiatry 2005; 62: 19–28.

    Article  CAS  PubMed  Google Scholar 

  14. Howes OD, Bhatnagar A, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS . A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 2004; 161: 361–363.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Gualin BD, Markowitz JS, Caley CF, Nesbitt LA, Dufresne RL . Clozapine-associated elevation in serum triglyceride. Am J psychiatry 1999; 156: 1270–1272.

    Google Scholar 

  16. Ghaeli P, Dufresne RL . Serum triglyceride levels in patients treated with clozapine. Am J health Syst Pharm 1996; 53: 2079–2081; prospective study.

    Article  CAS  PubMed  Google Scholar 

  17. Opgaard OS, Wang PH . IGF-1 is a matter of heart. Growth Horm. IGF Res 2005; 15: 89–94.

    CAS  Google Scholar 

  18. Ren J, Samson WK, Sowers JR . Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 1999; 31: 2049–2061.

    Article  CAS  PubMed  Google Scholar 

  19. Bleumink GS, Rietveld I, Janssen JA, van Rossum EF, Deckers JW, Hofman A et al. Insulin-like growth factor-I gene polymorphism and risk of heart failure (the Rotterdam Study). Am J Cardiol 2004; 94: 384–386.

    Article  CAS  PubMed  Google Scholar 

  20. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996; 28: 619–637.

    Article  CAS  PubMed  Google Scholar 

  21. Johnsen SP, Hundborg HH, Sorensen HT, Orskov H, Tjonneland A, Overvad K et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab 2005; 90: 5937–5941.

    Article  CAS  PubMed  Google Scholar 

  22. Colao A, Spiezia S, Di Somma C, Pivonello R, Marzullo P, Rota F et al. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J Endocrinol Invest 2005; 28: 440–448.

    Article  CAS  PubMed  Google Scholar 

  23. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T . Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case–control study. Circulation 2002; 106: 939–944.

    Article  CAS  Google Scholar 

  24. Melkersson KI, Hulting AL, Brismar KE . Different influences of classical antipsychotics and clozapine on glucose–insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999; 60: 783–791.

    Article  CAS  PubMed  Google Scholar 

  25. Khosravi MJ, Papanastasiou-Diamandi A, Mistry J . An ultrasensitive immunoassay for prostate-specific antigen based on conventional colorimetric detection. Clin Biochem 1995; 28: 407–414.

    Article  CAS  PubMed  Google Scholar 

  26. Wu MK, Bai YM, Huang CY, Wang CK, Lee SD . Outcomes of obese, clozapine-treated impatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatric Service 2007; 58: 544–550.

    Article  Google Scholar 

  27. Sharpe JK, Hills AP . Anthropometry and adiposity in a group of people with chronic mental illness. Aust N Z J Psychiatry 1998; 32: 77–81.

    Article  CAS  PubMed  Google Scholar 

  28. Frankenburg FR, Zanarini MC, Kando J, Centorrino F . Clozapine and body mass change. Biol Psychiatry 1998; 43: 520–524.

    Article  CAS  PubMed  Google Scholar 

  29. Bjorntorp P . Obesity and risk of cardiovascular disease. Acta Med Scand 1985; 218: 145–147.

    Article  CAS  PubMed  Google Scholar 

  30. Zimmet P . Epidemiology of diabetes mellitus and associated cardiovascular risk factors: focus on human immunodeficiency virus and psychiatric disorders. Am J Med 2005; 118 (Suppl 2): 3S–8S.

    PubMed  Google Scholar 

  31. Kato MM, Currier MB, Gomez CM, Hall L, Gonzalez-Blanco M . Prevalence of metabolic syndrome in hispanic and non-hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry 2004; 6: 74–77.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Zhao Z, Ksiezak-Reding H, Riggio S, Haroutunian V, Pasinetti GM . Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res 2006; 84: 1–14.

    Article  PubMed  Google Scholar 

  33. Caballero E . Obesity, diabetes, and the metabolic syndrome: new challenges in antipsychotic drug therapy. CNS Spectr 2003; 8 (11 Suppl 2): 19–22.

    Article  PubMed  Google Scholar 

  34. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL . Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37: 68–73.

    Article  CAS  PubMed  Google Scholar 

  35. Rasmussen MH, Frystyk J, Andersen T, Breum L, Christiansen JS, Hilsted J . The impact of obesity, fat distribution, and energy restriction on insulin-like growth factor-1 (IGF-1), IGF-binding protein-3, insulin, and growth hormone. Metabolism 1994; 43: 315–319.

    Article  CAS  PubMed  Google Scholar 

  36. Melkersson KI, Scordo MG, Gunes A, Dahl ML . Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry 2007; 68: 697–704.

    Article  CAS  PubMed  Google Scholar 

  37. Dunger D, Yuen K, Ong K . Insulin-like growth factor I and impaired glucose tolerance. Horm Res 2004; 62 (Suppl 1): 101–107.

    CAS  PubMed  Google Scholar 

  38. Hilding A, Brismar K, Degerblad M, Thorén M, Hall K . Altered relation between circulating levels of insulin-like growth factors-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 1995; 80: 2646–2652.

    CAS  PubMed  Google Scholar 

  39. Howes OD, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS . The effect of clozapine on factors controlling glucose homeostasis. J Clin Psychiatry 2004; 65: 1352–1355.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The study is supported by Grant VHYL-92-10 from Yu Li Veterans Hospital and Grant NSC 95-2314-B-039-043-MY3 from the National Science Council, Taiwan.

Author information

Author notes

  1. C-K Wang and S-D Lee: These authors contributed equally to this work.

Authors and Affiliations

  1. Section of Nutrition, Yu Li Veterans Hospital, Hualien, Taiwan

    M-K Wu

  2. Department and Graduate Institute of Nutritional Science, College of Health Care and Management, Chung Shan Medical University, Taichung, Taiwan

    M-K Wu & C-K Wang

  3. Graduate Institute of Chinese Medical Science, China Medical University, Taichung, Taiwan

    C-Y Huang

  4. Department of Psychiatry, Yu Li Veterans Hospital, Hualien, Taiwan

    Y J Liou

  5. Department of Physical Therapy, China Medical University, Taichung, Taiwan

    S-D Lee

Authors
  1. M-K Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C-Y Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y J Liou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C-K Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S-D Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S-D Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, MK., Huang, CY., Liou, Y. et al. Glucose–insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity. Int J Obes 32, 436–442 (2008). https://doi.org/10.1038/sj.ijo.0803750

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0803750

Keywords

This article is cited by

Search

Advanced search

Quick links